Abstract
Patients with cancer are frequently exposed to risk of renal injuries associated with disease-related or iatrogenic causes. Nephrotoxicity is a potential adverse effect of anti-cancer agents and may result in a variety of functional abnormalities, including glomerular or tubular dysfunction, hypertension and disturbance of the renal endocrine function. In this review article, we comprehensively discuss the incidence, clinical presentation, prevention and management of anti-cancer agent-induced renal dysfunction. We focus on both relatively new anti-cancer agents (bevacizumab, gefitinib, gemcitabine, imatinib, rituximab and trastuzumab) and traditional agents (cisplatin, methotrexate, ifosfamide and taxanes) to cover a selection of the most frequently used anti-cancer agents. Increased understanding of the mechanism of renal injury by these agents is considered to be important for developing novel anti-cancer agents that have far fewer adverse effects on kidneys.
Keywords: Acute kidney injury, anti-cancer agents, cisplatin, chemotherapy, electrolyte abnormality, nephrotoxicity.
Anti-Cancer Agents in Medicinal Chemistry
Title:Anti-Cancer Agent-Induced Nephrotoxicity
Volume: 14 Issue: 7
Author(s): Hirotaka Fukasawa, Ryuichi Furuya, Hideo Yasuda, Tatsuo Yamamoto, Akira Hishida and Masatoshi Kitagawa
Affiliation:
Keywords: Acute kidney injury, anti-cancer agents, cisplatin, chemotherapy, electrolyte abnormality, nephrotoxicity.
Abstract: Patients with cancer are frequently exposed to risk of renal injuries associated with disease-related or iatrogenic causes. Nephrotoxicity is a potential adverse effect of anti-cancer agents and may result in a variety of functional abnormalities, including glomerular or tubular dysfunction, hypertension and disturbance of the renal endocrine function. In this review article, we comprehensively discuss the incidence, clinical presentation, prevention and management of anti-cancer agent-induced renal dysfunction. We focus on both relatively new anti-cancer agents (bevacizumab, gefitinib, gemcitabine, imatinib, rituximab and trastuzumab) and traditional agents (cisplatin, methotrexate, ifosfamide and taxanes) to cover a selection of the most frequently used anti-cancer agents. Increased understanding of the mechanism of renal injury by these agents is considered to be important for developing novel anti-cancer agents that have far fewer adverse effects on kidneys.
Export Options
About this article
Cite this article as:
Fukasawa Hirotaka, Furuya Ryuichi, Yasuda Hideo, Yamamoto Tatsuo, Hishida Akira and Kitagawa Masatoshi, Anti-Cancer Agent-Induced Nephrotoxicity, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (7) . https://dx.doi.org/10.2174/1871520614666140127105809
DOI https://dx.doi.org/10.2174/1871520614666140127105809 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews Surgery for Severe Obesity: Indications, Techniques, Mechanisms of Weight Loss and Diabetes Resolution
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Neuropeptides and Gastric Mucosal Homeostasis
Current Topics in Medicinal Chemistry Biomarkers for Diagnosing and Staging of Fabry Disease
Current Medicinal Chemistry The Impact of Inflammatory Profile on Selenium Levels in Hemodialysis Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Endocannabinoid Metabolic Pathways and Enzymes
Current Drug Targets - CNS & Neurological Disorders Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women
Current Pharmaceutical Design The GH/IGF-1 Axis and Heart Failure
Current Cardiology Reviews Multi-Aspect Candidates for Repositioning: Data Fusion Methods Using Heterogeneous Information Sources
Current Medicinal Chemistry Leptin: A Promising Therapeutic Target with Pleiotropic Action Besides Body Weight Regulation
Current Drug Targets Phytotherapy of Hypertension: An Updated Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Selections
Recent Patents on Cardiovascular Drug Discovery Goal Directed Fluid Therapy
Current Pharmaceutical Design Molecular Docking Study of Catecholamines and [4-(Propan-2-yl) Phenyl]Carbamic acid with Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research The Effectiveness of Nurse- and Pharmacist-Directed Care in Diabetes Disease Management:A Narrative Review
Current Diabetes Reviews Transforming Growth Factor-Beta Family: Advances in Vascular Function and Signaling
Current Protein & Peptide Science Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology Intracoronary Injection of Drugs to Treat No – Reflow Phenomenon and Microcirculatory Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry